世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

臨床試験イメージング市場：ソフトウェア＆サービス（オペレーショナルイメージング、試験デザイン）、モダリティ（CT、MRI、X線、PET、超音波、ECHO）、治療領域（感染症、腫瘍、中枢神経系、CVD）、エンドユーザー（製薬、バイオテクノロジー、CRO）、地域別 - 2028年までの世界予測


Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) & Region - Global Forecast to 2028

世界の臨床試験イメージング市場は、2023年の13億米ドルから2028年には19億米ドルに達し、予測期間中の年平均成長率は7.8％と予測されている。市場の拡大は、製薬・バイオテクノロジー分野の拡大、研究開発投資の... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年8月18日 US$4,950
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		175 149 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の臨床試験イメージング市場は、2023年の13億米ドルから2028年には19億米ドルに達し、予測期間中の年平均成長率は7.8％と予測されている。市場の拡大は、製薬・バイオテクノロジー分野の拡大、研究開発投資の拡大、CRO（医薬品開発業務受託機関）の急増などの要因によって推進されている。一方、イメージングシステムの導入コストの高さや臨床試験費用の高さが、予測期間中の同市場の成長を阻害する主な要因となっている。
"サービス＆ソフトウェア別では、サービスセグメントが予測期間中の臨床試験イメージング市場で最も高い成長率を占めた"
臨床試験イメージング市場は、製品に基づいてサービスとソフトウェアに区分される。2022年の臨床試験イメージング市場では、サービス分野が最も高い成長率を占めた。タイプ別に見ると、サービスセグメントはさらに、オペレーショナルイメージングサービス、リーダー分析サービス、システム＆テクニカルサポートサービス、トライアルデザインコンサルティングサービスに分類される。このセグメントの成長は、主に研究開発費の増加、臨床試験の拡大、新しい病気の治療と診断の需要に起因している。
"医療機器メーカーセグメントが最も高いCAGRを占める"
臨床試験イメージング市場は、エンドユーザーに基づき、製薬企業、バイオテクノロジー企業、医療機器メーカー、受託研究機関、学術・政府研究機関、その他のエンドユーザーに区分される。2022年には、医療機器メーカーセグメントが最も高い成長率を占めた。これは、医療機器メーカーによる研究開発費と研究開発活動の増加、医療機器市場の拡大が医療機器メーカーセグメントの主な成長要因であるためと考えられる。
「アジア太平洋：最も急成長している地域の臨床試験イメージング市場"
世界の臨床試験イメージング市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分される。アジア太平洋地域は予測期間中に最も高いCAGRを記録すると予測されている。研究開発投資の急増とアジア新興国への医薬品研究のアウトソーシング志向の高まりが、市場拡大を推進する極めて重要な触媒となっている。

本レポートのために実施した一次インタビューは以下のように分類できる：

- 企業タイプ別Tier1：40％、Tier2：30％、Tier3：30
- 役職別Cレベル：27％、Dレベル：18％、その他：55
- 地域別北米：51％、欧州：21％、アジア太平洋地域：18％、中南米：6％、中東・アフリカ：4
主要企業は、ICON plc.(アイルランド）、BioTelemetry Inc.（米国）、Biomedical Systems Corporation（米国）、Medpace Holdings, Inc.(英国）、Resonance Health Ltd. （オーストラリア）、Radiant Sage.(オーストラリア）、Radiant Sage LLC.(米国）、BioClinica Inc.（米国）、Intrinsic Imaging LLC.(米国）、Cardiovascular Imaging Technologies LLC.(米国）、Medical Metrics Inc.（米国）、Prism Clinical Imaging, Inc.（米国）、Boston Imaging Core Lab LLC.(米国）、anagram 4 clinical trials（スペイン）、Lyscaut Medical Imaging Company（ベルギー）、Calyx Group（英国）、Bioseptive Inc.（カナダ）、ProScan Imaging LLC.(米国）、マイクロン社（日本）、Imaging Endpoints LI, LLC（米国）、Perspectum Ltd. （英国）、Pharmtrace k.(英国）、Pharmtrace klinische Entwicklung GmbH（ドイツ）、WorldCare Clinical, LLC（米国）、Median Technologies（フランス）、Invicro.LLC.(米国）。
調査範囲
この調査レポートは、臨床試験イメージング市場をサービス＆ソフトウェア、モダリティ、治療分野、エンドユーザー、地域別に分類しています。臨床試験イメージング市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、契約、パートナーシップ、合意、新製品・サービスの発表、M&A、臨床試験イメージング市場に関連する最近の動向に関する洞察を提供しています。臨床試験イメージング市場のエコシステムにおける今後の新興企業の競争分析も本レポートでカバーしています。
レポート購入の主な利点
本レポートは、臨床試験イメージング市場全体とそのサブセグメントに関する収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 臨床試験イメージング市場の成長に影響を与える主な促進要因、阻害要因、機会、課題の分析
- 製品開発/イノベーション：臨床試験イメージング市場における今後の技術、研究開発活動、新製品およびサービスの発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 本レポートは、様々な地域における臨床試験イメージング市場を分析しています。
- 市場の多様化：臨床試験イメージング市場における新製品＆サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競合評価：ICON plc.（アイルランド）、BioTelemet.(アイルランド）、BioTelemetry Inc.（米国）、Biomedical Systems Corporation（米国）、Medpace Holdings, Inc.

ページTOPに戻る


目次

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.2.2 MARKETS COVERED 26
FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION 26
1.2.3 GEOGRAPHIC SCOPE 27
1.2.4 YEARS CONSIDERED 27
1.2.5 CURRENCY CONSIDERED 28
1.3 LIMITATIONS 28
1.4 STAKEHOLDERS 28
1.5 SUMMARY OF CHANGES 29
1.5.1 RECESSION IMPACT 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.2 RESEARCH APPROACH 30
FIGURE 2 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN 30
2.2.1 SECONDARY DATA 30
2.2.1.1 Key data from secondary sources 31
2.2.2 PRIMARY DATA 32
FIGURE 3 BREAKDOWN OF INTERVIEWS: SUPPLY AND DEMAND SIDE 32
2.2.2.1 Key data from primary sources 33
2.2.2.2 Key industry insights 34
2.2.2.3 Breakdown of primary interviews 34
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS 34
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.3 MARKET SIZE ESTIMATION 35
2.3.1 BOTTOM-UP APPROACH 36
2.3.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
2.3.1.2 Approach 2: Presentations of companies and primary interviews 36
2.3.1.3 Growth forecast 37
2.3.1.4 CAGR projections 37
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
2.3.2 TOP-DOWN APPROACH 38
FIGURE 8 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH 38
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 39
FIGURE 9 DATA TRIANGULATION METHODOLOGY 39
2.5 STUDY ASSUMPTIONS 40
2.6 RISK ASSESSMENT 40
2.7 LIMITATIONS 41
2.8 CLINICAL TRIAL IMAGING MARKET: RECESSION IMPACT 41
3 EXECUTIVE SUMMARY 43
FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION) 44
FIGURE 12 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 45
FIGURE 13 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46
FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 47
4 PREMIUM INSIGHTS 48
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW 48
FIGURE 15 RISING R&D SPENDING TO DRIVE MARKET GROWTH 48
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2022 VS. 2028 48
FIGURE 16 SERVICES TO HOLD LARGEST MARKET SHARE TILL 2028 48
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2023 VS. 2028 49
FIGURE 17 COMPUTED TOMOGRAPHY TO COMMAND LARGEST SHARE OVER FORECAST PERIOD 49
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028 49
FIGURE 18 ONCOLOGY TO DOMINATE MARKET, BY THERAPEUTIC AREA, TILL 2028 49
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2023 VS. 2028 50
FIGURE 19 PHARMACEUTICAL COMPANIES TO RETAIN MARKET LEADERSHIP OVER FORECAST PERIOD 50
4.6 CLINICAL TRIAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE TILL 2028 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Increasing R&D spending 52
5.2.1.2 Growth of pharmaceutical and biotechnology industries 52
5.2.1.3 Increasing number of CROs 52
5.2.2 RESTRAINTS 53
5.2.2.1 High implementation cost of imaging systems 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Growth opportunities in emerging economies 53
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals 53
5.2.4 CHALLENGES 54
5.2.4.1 High cost of clinical trials 54
5.3 PRICING ANALYSIS 54
TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2022) 54
5.4 PATENT ANALYSIS 55
5.5 TRADE ANALYSIS 55
5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUSES 55
TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 55
TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 56
5.5.2 TRADE ANALYSIS FOR CT APPARATUSES 56
TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 56
TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 57
5.6 VALUE CHAIN ANALYSIS 57
FIGURE 22 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS 57
5.7 SUPPLY CHAIN ANALYSIS 58
FIGURE 23 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS 59
5.8 ECOSYSTEM ANALYSIS 59
FIGURE 24 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS 59
TABLE 6 COMPANY ROLE IN ECOSYSTEM 60
5.9 PORTER’S FIVE FORCES ANALYSIS 61
TABLE 7 CLINICAL TRIAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS 61
5.9.1 THREAT OF NEW ENTRANTS 61
5.9.2 THREAT OF SUBSTITUTES 61
5.9.3 BARGAINING POWER OF BUYERS 61
5.9.4 BARGAINING POWER OF SUPPLIERS 61
5.9.5 DEGREE OF COMPETITION 61
5.10 PESTLE ANALYSIS 62
5.11 REGULATORY LANDSCAPE 62
5.11.1 NORTH AMERICA 62
5.11.1.1 US 62
5.11.1.2 CANADA 63
5.11.2 EUROPE 63
5.11.3 ASIA PACIFIC 63
5.11.3.1 Japan 63
5.11.3.2 India 63
5.11.3.3 China 64
5.11.4 LATIN AMERICA 64
5.11.4.1 Brazil 64
5.11.4.2 Mexico 64
5.11.5 MIDDLE EAST 65
5.11.6 AFRICA 65
5.12 TECHNOLOGY ANALYSIS 65
5.13 CLINICAL TRIAL IMAGING: DISRUPTIVE TECHNOLOGIES 66
FIGURE 25 REVENUE SHIFT IN CLINICAL TRIAL IMAGING MARKET 66
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 67
6.1 INTRODUCTION 68
TABLE 8 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 68
6.2 SERVICES 68
TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 68
TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 69
6.2.1 OPERATIONAL IMAGING SERVICES 69
6.2.1.1 Rising number of CROs to drive market 69
TABLE 11 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 69
6.2.2 READ ANALYSIS SERVICES 70
6.2.2.1 Growing clinical trial activity to support growth 70
TABLE 12 READ ANALYSIS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 70
6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES 70
6.2.3.1 Need for continuous technical support to drive market 70
TABLE 13 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 71
6.2.4 TRIAL DESIGN & CONSULTING SERVICES 71
6.2.4.1 Rising R&D spending and need for clinical trial support to boost outsourcing 71
TABLE 14 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 71
6.3 SOFTWARE 72
6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE TO BOOST ADOPTION 72
TABLE 15 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 72
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY 73
7.1 INTRODUCTION 74
TABLE 16 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 74
7.2 CT 74
7.2.1 QUICK RESULTS AND LACK OF VISIBLE SIDE EFFECTS TO DRIVE ADOPTION 74
TABLE 17 CLINICAL TRIAL IMAGING MARKET FOR CT, BY REGION, 2021–2028 75
7.3 MRI 75
7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET 75
TABLE 18 CLINICAL TRIAL IMAGING MARKET FOR MRI, BY REGION, 2021–2028 (USD MILLION) 76
7.4 ULTRASOUND 76
7.4.1 HIGH SAFETY TO ENSURE CONTINUED DEMAND 76
TABLE 19 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION, 2021–2028 (USD MILLION) 77
7.5 PET 77
7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS TO BOOST ADOPTION 77
TABLE 20 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION, 2021–2028 (USD MILLION) 78
7.6 X-RAY 78
7.6.1 WIDE USAGE IN BONE, CHEST, AND DENTAL IMAGING TO DRIVE MARKET 78
TABLE 21 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION, 2021–2028 (USD MILLION) 79
7.7 ECHOCARDIOGRAPHY 79
7.7.1 ADVANTAGES IN DEFINING AND QUALIFYING POPULATIONS TO BOOST USAGE 79
TABLE 22 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2021–2028 (USD MILLION) 79
7.8 OTHER MODALITIES 80
TABLE 23 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2021–2028 (USD MILLION) 80
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 81
8.1 INTRODUCTION 82
TABLE 24 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 82
8.2 ONCOLOGY 82
8.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET 82
TABLE 25 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 83
8.3 INFECTIOUS DISEASES 83
8.3.1 RISING DRUG DISCOVERY ACTIVITY TO BOOST DEMAND FOR IMAGING 83
TABLE 26 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 84
8.4 NEUROLOGY 84
8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE MARKET 84
TABLE 27 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 85
8.5 CVS DISORDERS 85
8.5.1 HIGH MORTALITY RATE OF CVD TO INCREASE CLINICAL TRIAL ACTIVITY 85
TABLE 28 CLINICAL TRIAL IMAGING MARKET FOR CVS DISORDERS, BY REGION, 2021–2028 (USD MILLION) 86
8.6 ENDOCRINOLOGY 86
8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET 86
TABLE 29 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 87
8.7 IMMUNOLOGICAL DISORDERS 87
8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT DEMAND FOR IMAGING IN TRIALS 87
TABLE 30 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 87
8.8 OTHER THERAPEUTIC AREAS 88
TABLE 31 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 88
9 CLINICAL TRIAL IMAGING MARKET, BY END USER 89
9.1 INTRODUCTION 90
TABLE 32 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 90
9.2 PHARMACEUTICAL COMPANIES 90
9.2.1 PHARMA COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET 90
FIGURE 26 RISING R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION) 91
TABLE 33 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 91
9.3 BIOTECHNOLOGY COMPANIES 92
9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE MARKET 92
TABLE 34 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2020 92
TABLE 35 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 93
9.4 MEDICAL DEVICE MANUFACTURERS 93
9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO SUPPORT GROWTH 93
TABLE 36 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2021–2028 (USD MILLION) 94
9.5 CROS 94
9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET 94
TABLE 37 CLINICAL TRIAL IMAGING MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION) 95
9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 95
9.6.1 INCREASING RESEARCH ACTIVITY TO DRIVE MARKET 95
TABLE 38 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 96
9.7 OTHER END USERS 96
TABLE 39 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 96
10 CLINICAL TRIAL IMAGING MARKET, BY REGION 97
10.1 INTRODUCTION 98
TABLE 40 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2021–2028 (USD MILLION) 98
10.2 NORTH AMERICA 98
FIGURE 27 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 99
10.2.1 NORTH AMERICA: RECESSION IMPACT 99
TABLE 41 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 42 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 100
TABLE 43 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 100
TABLE 44 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 101
10.2.2 US 101
10.2.2.1 Rising biopharma investment to favor market growth 101
TABLE 45 US: PRODUCT APPROVALS IN CLINICAL TRIAL IMAGING 101
TABLE 46 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 102
TABLE 47 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 102
TABLE 48 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 103
10.2.3 CANADA 103
10.2.3.1 Rising per capita healthcare spending to drive market 103
TABLE 49 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 103
TABLE 50 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 104
TABLE 51 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 104
10.3 EUROPE 105
10.3.1 EUROPE: RECESSION IMPACT 105
TABLE 52 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 53 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 106
TABLE 54 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 107
TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 107
10.3.2 GERMANY 108
10.3.2.1 Germany to dominate clinical trial imaging market in Europe 108
TABLE 56 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 108
TABLE 57 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 108
TABLE 58 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 109
10.3.3 UK 109
10.3.3.1 Favorable government initiatives and growing R&D spending to drive market 109
TABLE 59 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 109
TABLE 60 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 110
TABLE 61 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 110
10.3.4 FRANCE 111
10.3.4.1 Presence of leading pharmaceutical companies to support growth 111
TABLE 62 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 111
TABLE 63 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 111
TABLE 64 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 112
10.3.5 ITALY 112
10.3.5.1 Increasing drug approvals to ensure sustained demand for clinical trial imaging 112
TABLE 65 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 112
TABLE 66 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 113
TABLE 67 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 113
10.3.6 SPAIN 113
10.3.6.1 Increasing biologics production to support market growth 113
TABLE 68 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 114
TABLE 69 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 114
TABLE 70 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 115
10.3.7 REST OF EUROPE 115
TABLE 71 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 115
TABLE 72 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 116
TABLE 73 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 116
10.4 ASIA PACIFIC 117
FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 117
10.4.1 ASIA PACIFIC: RECESSION IMPACT 118
TABLE 74 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 75 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 118
TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 119
TABLE 77 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.4.2 CHINA 120
10.4.2.1 China to dominate APAC market throughout forecast period 120
TABLE 78 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 120
TABLE 79 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 120
TABLE 80 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.4.3 JAPAN 121
10.4.3.1 Rising population and healthcare expenditure to favor market growth 121
TABLE 81 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 121
TABLE 82 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 122
TABLE 83 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 122
10.4.4 INDIA 123
10.4.4.1 Rising R&D investment to boost adoption of clinical trial imaging 123
TABLE 84 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 123
TABLE 85 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 124
TABLE 86 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 124
10.4.5 REST OF ASIA PACIFIC 125
TABLE 87 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 125
TABLE 88 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 125
TABLE 89 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 126
10.5 LATIN AMERICA 126
10.5.1 LOW COST OF RESOURCES, TAX ADVANTAGES TO ATTRACT PLAYER INTEREST 126
10.5.2 LATIN AMERICA: RECESSION IMPACT 127
TABLE 90 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 127
TABLE 91 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 127
TABLE 92 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 128
10.6 MIDDLE EAST & AFRICA 128
10.6.1 RISING RESEARCH FUNDING AND PARTNERSHIPS TO DRIVE MARKET 128
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 129
TABLE 93 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 129
TABLE 94 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 129
TABLE 95 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
11 COMPETITIVE LANDSCAPE 131
11.1 OVERVIEW 131
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 131
11.2.1 RIGHT-TO-WIN APPROACHES ADOPTED BY PLAYERS 131
TABLE 96 CLINICAL TRIAL IMAGING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 131
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 133
FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022) 133
11.4 MARKET SHARE ANALYSIS 133
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 133
TABLE 97 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION 134
11.5 COMPANY EVALUATION MATRIX (2022) 135
11.5.1 STARS 135
11.5.2 EMERGING LEADERS 135
11.5.3 PERVASIVE PLAYERS 135
11.5.4 PARTICIPANTS 135
FIGURE 31 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX, 2022 136
11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 137
11.6.1 PROGRESSIVE COMPANIES 137
11.6.2 STARTING BLOCKS 137
11.6.3 RESPONSIVE COMPANIES 137
11.6.4 DYNAMIC COMPANIES 137
FIGURE 32 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATIRX FOR STARTUPS/SMES, 2022 138
11.7 COMPETITIVE BENCHMARKING 138
FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF KEY PLAYERS 138
TABLE 98 COMPANY PRODUCT FOOTPRINT 139
TABLE 99 COMPANY GEOGRAPHICAL FOOTPRINT 139
11.8 COMPETITIVE SCENARIO 139
11.8.1 PRODUCT LAUNCHES & APPROVALS 139
TABLE 100 KEY PRODUCT LAUNCHES & APPROVALS (2020–2023) 139
11.8.2 DEALS 140
TABLE 101 KEY DEALS (2020–2023) 140
12 COMPANY PROFILES 141
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1 KEY PLAYERS 141
12.1.1 ICON PLC. 141
TABLE 102 ICON PLC.: BUSINESS OVERVIEW 141
FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2022) 142
12.1.2 BIOTELEMETRY (PHILIPS) 144
TABLE 103 BIOTELEMETRY: BUSINESS OVERVIEW 144
FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2022) 145
12.1.3 MEDPACE HOLDINGS INC. 147
TABLE 104 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 147
FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2022) 147
12.1.4 BIOMEDICAL SYSTEMS CORPORATION (ERT CLINICAL) 149
TABLE 105 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 149
12.1.5 BIOCLINICA INC. (CLARIO) 150
TABLE 106 BIOCLINICA INC.: BUSINESS OVERVIEW 150
12.1.6 IXICO PLC. 154
TABLE 107 IXICO PLC.: BUSINESS OVERVIEW 154
FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2022) 154
12.1.7 RESONANCE HEALTH ANALYSIS SERVICES (RESONANCE HEALTH) 157
TABLE 108 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW 157
FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2022) 157
12.1.8 RADIANT SAGE LLC 159
TABLE 109 RADIANT SAGE LLC: BUSINESS OVERVIEW 159
12.1.9 INTRINSIC IMAGING (WCG CLINICAL) 160
TABLE 110 WCG CLINICAL: BUSINESS OVERVIEW 160
12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES 161
TABLE 111 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW 161
12.2 OTHER PLAYERS 162
12.2.1 MEDICAL METRICS 162
12.2.2 PRISM CLINICAL IMAGING 163
12.2.3 BOSTON IMAGING CORE LAB 164
12.2.4 ANAGRAM 4 CLINICAL TRIALS 164
12.2.5 LYSCAUT MEDICAL IMAGING COMPANY 165
12.2.6 CALYX GROUP 165
12.2.7 BIOSPECTIVE 166
12.2.8 PROSCAN IMAGING 167
12.2.9 MICRON, INC. 167
12.2.10 IMAGING ENDPOINTS LI LLC. 168
12.2.11 PERSPECTUM 169
12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG GMBH 169
12.2.13 WORLDCARE CLINICAL 170
12.2.14 MEDIAN TECHNOLOGIES 170
12.2.15 INVICRO. LLC. 171
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX 172
13.1 DISCUSSION GUIDE 172
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 176
13.3 CUSTOMIZATION OPTIONS 178
13.4 RELATED REPORTS 178
13.5 AUTHOR DETAILS 179

　

ページTOPに戻る


　

Summary

The global clinical trial imaging market is projected to reach USD 1.9 billion by 2028 from USD 1.3 billion in 2023, at a CAGR of 7.8% during the forecast period. The market's expansion is propelled by factors including the expansion of the pharmaceutical and biotechnology sectors, escalated research and development investments, and the proliferation of Contract Research Organizations (CROs). On the other hand, the high implementation cost of the imaging system and high cost of clinical trials are the major factors hindering the growth of this market during the forecast period.
“The service segment accounted for the highest growth rate in the clinical trial imaging market, by service & software, during the forecast period”
The clinical trial imaging market is segmented into services and software based on product. In 2022, the service segment accounted for the highest growth rate in the clinical trial imaging market. Based on type, the services segment is further classified into operational imaging services, reader analysis services, system & technical support services, and trial design consulting services. The growth of this segment is primarily attributed to the rising R&D spending, expanding clinical trials, and the demand for new disease treatment and diagnostics.
“Medical device manufacturers segment accounted for the highest CAGR”
Based on end user, the clinical trial imaging market is segmented into pharmaceutical companies, biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes, and other end users. In 2022, the medical device manufacturers segment accounted for the highest growth rate. This can be attributed to the increasing R&D expenditure and R&D activities by medical device manufacturers and the expanding medical devices market are the primary growth drivers of the medical device manufacturers segment.
“Asia Pacific: The fastest-growing region clinical trial imaging market”
The global clinical trial imaging market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. The surge in research and development investments and the growing inclination towards outsourcing pharmaceutical research to emerging Asian nations are the pivotal catalysts propelling the market's expansion.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).
Research Coverage:
This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the clinical trial imaging market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.
• Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.2.2 MARKETS COVERED 26
FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION 26
1.2.3 GEOGRAPHIC SCOPE 27
1.2.4 YEARS CONSIDERED 27
1.2.5 CURRENCY CONSIDERED 28
1.3 LIMITATIONS 28
1.4 STAKEHOLDERS 28
1.5 SUMMARY OF CHANGES 29
1.5.1 RECESSION IMPACT 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.2 RESEARCH APPROACH 30
FIGURE 2 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN 30
2.2.1 SECONDARY DATA 30
2.2.1.1 Key data from secondary sources 31
2.2.2 PRIMARY DATA 32
FIGURE 3 BREAKDOWN OF INTERVIEWS: SUPPLY AND DEMAND SIDE 32
2.2.2.1 Key data from primary sources 33
2.2.2.2 Key industry insights 34
2.2.2.3 Breakdown of primary interviews 34
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS 34
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.3 MARKET SIZE ESTIMATION 35
2.3.1 BOTTOM-UP APPROACH 36
2.3.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
2.3.1.2 Approach 2: Presentations of companies and primary interviews 36
2.3.1.3 Growth forecast 37
2.3.1.4 CAGR projections 37
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
2.3.2 TOP-DOWN APPROACH 38
FIGURE 8 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH 38
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 39
FIGURE 9 DATA TRIANGULATION METHODOLOGY 39
2.5 STUDY ASSUMPTIONS 40
2.6 RISK ASSESSMENT 40
2.7 LIMITATIONS 41
2.8 CLINICAL TRIAL IMAGING MARKET: RECESSION IMPACT 41
3 EXECUTIVE SUMMARY 43
FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION) 44
FIGURE 12 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 45
FIGURE 13 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46
FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 47
4 PREMIUM INSIGHTS 48
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW 48
FIGURE 15 RISING R&D SPENDING TO DRIVE MARKET GROWTH 48
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2022 VS. 2028 48
FIGURE 16 SERVICES TO HOLD LARGEST MARKET SHARE TILL 2028 48
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2023 VS. 2028 49
FIGURE 17 COMPUTED TOMOGRAPHY TO COMMAND LARGEST SHARE OVER FORECAST PERIOD 49
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028 49
FIGURE 18 ONCOLOGY TO DOMINATE MARKET, BY THERAPEUTIC AREA, TILL 2028 49
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2023 VS. 2028 50
FIGURE 19 PHARMACEUTICAL COMPANIES TO RETAIN MARKET LEADERSHIP OVER FORECAST PERIOD 50
4.6 CLINICAL TRIAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE TILL 2028 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Increasing R&D spending 52
5.2.1.2 Growth of pharmaceutical and biotechnology industries 52
5.2.1.3 Increasing number of CROs 52
5.2.2 RESTRAINTS 53
5.2.2.1 High implementation cost of imaging systems 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Growth opportunities in emerging economies 53
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals 53
5.2.4 CHALLENGES 54
5.2.4.1 High cost of clinical trials 54
5.3 PRICING ANALYSIS 54
TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2022) 54
5.4 PATENT ANALYSIS 55
5.5 TRADE ANALYSIS 55
5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUSES 55
TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 55
TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 56
5.5.2 TRADE ANALYSIS FOR CT APPARATUSES 56
TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 56
TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION) 57
5.6 VALUE CHAIN ANALYSIS 57
FIGURE 22 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS 57
5.7 SUPPLY CHAIN ANALYSIS 58
FIGURE 23 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS 59
5.8 ECOSYSTEM ANALYSIS 59
FIGURE 24 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS 59
TABLE 6 COMPANY ROLE IN ECOSYSTEM 60
5.9 PORTER’S FIVE FORCES ANALYSIS 61
TABLE 7 CLINICAL TRIAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS 61
5.9.1 THREAT OF NEW ENTRANTS 61
5.9.2 THREAT OF SUBSTITUTES 61
5.9.3 BARGAINING POWER OF BUYERS 61
5.9.4 BARGAINING POWER OF SUPPLIERS 61
5.9.5 DEGREE OF COMPETITION 61
5.10 PESTLE ANALYSIS 62
5.11 REGULATORY LANDSCAPE 62
5.11.1 NORTH AMERICA 62
5.11.1.1 US 62
5.11.1.2 CANADA 63
5.11.2 EUROPE 63
5.11.3 ASIA PACIFIC 63
5.11.3.1 Japan 63
5.11.3.2 India 63
5.11.3.3 China 64
5.11.4 LATIN AMERICA 64
5.11.4.1 Brazil 64
5.11.4.2 Mexico 64
5.11.5 MIDDLE EAST 65
5.11.6 AFRICA 65
5.12 TECHNOLOGY ANALYSIS 65
5.13 CLINICAL TRIAL IMAGING: DISRUPTIVE TECHNOLOGIES 66
FIGURE 25 REVENUE SHIFT IN CLINICAL TRIAL IMAGING MARKET 66
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 67
6.1 INTRODUCTION 68
TABLE 8 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 68
6.2 SERVICES 68
TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 68
TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 69
6.2.1 OPERATIONAL IMAGING SERVICES 69
6.2.1.1 Rising number of CROs to drive market 69
TABLE 11 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 69
6.2.2 READ ANALYSIS SERVICES 70
6.2.2.1 Growing clinical trial activity to support growth 70
TABLE 12 READ ANALYSIS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 70
6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES 70
6.2.3.1 Need for continuous technical support to drive market 70
TABLE 13 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 71
6.2.4 TRIAL DESIGN & CONSULTING SERVICES 71
6.2.4.1 Rising R&D spending and need for clinical trial support to boost outsourcing 71
TABLE 14 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 71
6.3 SOFTWARE 72
6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE TO BOOST ADOPTION 72
TABLE 15 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 72
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY 73
7.1 INTRODUCTION 74
TABLE 16 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 74
7.2 CT 74
7.2.1 QUICK RESULTS AND LACK OF VISIBLE SIDE EFFECTS TO DRIVE ADOPTION 74
TABLE 17 CLINICAL TRIAL IMAGING MARKET FOR CT, BY REGION, 2021–2028 75
7.3 MRI 75
7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET 75
TABLE 18 CLINICAL TRIAL IMAGING MARKET FOR MRI, BY REGION, 2021–2028 (USD MILLION) 76
7.4 ULTRASOUND 76
7.4.1 HIGH SAFETY TO ENSURE CONTINUED DEMAND 76
TABLE 19 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION, 2021–2028 (USD MILLION) 77
7.5 PET 77
7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS TO BOOST ADOPTION 77
TABLE 20 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION, 2021–2028 (USD MILLION) 78
7.6 X-RAY 78
7.6.1 WIDE USAGE IN BONE, CHEST, AND DENTAL IMAGING TO DRIVE MARKET 78
TABLE 21 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION, 2021–2028 (USD MILLION) 79
7.7 ECHOCARDIOGRAPHY 79
7.7.1 ADVANTAGES IN DEFINING AND QUALIFYING POPULATIONS TO BOOST USAGE 79
TABLE 22 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2021–2028 (USD MILLION) 79
7.8 OTHER MODALITIES 80
TABLE 23 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2021–2028 (USD MILLION) 80
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 81
8.1 INTRODUCTION 82
TABLE 24 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 82
8.2 ONCOLOGY 82
8.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET 82
TABLE 25 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 83
8.3 INFECTIOUS DISEASES 83
8.3.1 RISING DRUG DISCOVERY ACTIVITY TO BOOST DEMAND FOR IMAGING 83
TABLE 26 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 84
8.4 NEUROLOGY 84
8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE MARKET 84
TABLE 27 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 85
8.5 CVS DISORDERS 85
8.5.1 HIGH MORTALITY RATE OF CVD TO INCREASE CLINICAL TRIAL ACTIVITY 85
TABLE 28 CLINICAL TRIAL IMAGING MARKET FOR CVS DISORDERS, BY REGION, 2021–2028 (USD MILLION) 86
8.6 ENDOCRINOLOGY 86
8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET 86
TABLE 29 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 87
8.7 IMMUNOLOGICAL DISORDERS 87
8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT DEMAND FOR IMAGING IN TRIALS 87
TABLE 30 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 87
8.8 OTHER THERAPEUTIC AREAS 88
TABLE 31 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 88
9 CLINICAL TRIAL IMAGING MARKET, BY END USER 89
9.1 INTRODUCTION 90
TABLE 32 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 90
9.2 PHARMACEUTICAL COMPANIES 90
9.2.1 PHARMA COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET 90
FIGURE 26 RISING R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION) 91
TABLE 33 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 91
9.3 BIOTECHNOLOGY COMPANIES 92
9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE MARKET 92
TABLE 34 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2020 92
TABLE 35 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 93
9.4 MEDICAL DEVICE MANUFACTURERS 93
9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO SUPPORT GROWTH 93
TABLE 36 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2021–2028 (USD MILLION) 94
9.5 CROS 94
9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET 94
TABLE 37 CLINICAL TRIAL IMAGING MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION) 95
9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 95
9.6.1 INCREASING RESEARCH ACTIVITY TO DRIVE MARKET 95
TABLE 38 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 96
9.7 OTHER END USERS 96
TABLE 39 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 96
10 CLINICAL TRIAL IMAGING MARKET, BY REGION 97
10.1 INTRODUCTION 98
TABLE 40 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2021–2028 (USD MILLION) 98
10.2 NORTH AMERICA 98
FIGURE 27 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 99
10.2.1 NORTH AMERICA: RECESSION IMPACT 99
TABLE 41 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 42 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 100
TABLE 43 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 100
TABLE 44 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 101
10.2.2 US 101
10.2.2.1 Rising biopharma investment to favor market growth 101
TABLE 45 US: PRODUCT APPROVALS IN CLINICAL TRIAL IMAGING 101
TABLE 46 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 102
TABLE 47 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 102
TABLE 48 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 103
10.2.3 CANADA 103
10.2.3.1 Rising per capita healthcare spending to drive market 103
TABLE 49 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 103
TABLE 50 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 104
TABLE 51 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 104
10.3 EUROPE 105
10.3.1 EUROPE: RECESSION IMPACT 105
TABLE 52 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 53 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 106
TABLE 54 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 107
TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 107
10.3.2 GERMANY 108
10.3.2.1 Germany to dominate clinical trial imaging market in Europe 108
TABLE 56 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 108
TABLE 57 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 108
TABLE 58 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 109
10.3.3 UK 109
10.3.3.1 Favorable government initiatives and growing R&D spending to drive market 109
TABLE 59 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 109
TABLE 60 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 110
TABLE 61 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 110
10.3.4 FRANCE 111
10.3.4.1 Presence of leading pharmaceutical companies to support growth 111
TABLE 62 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 111
TABLE 63 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 111
TABLE 64 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 112
10.3.5 ITALY 112
10.3.5.1 Increasing drug approvals to ensure sustained demand for clinical trial imaging 112
TABLE 65 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 112
TABLE 66 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 113
TABLE 67 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 113
10.3.6 SPAIN 113
10.3.6.1 Increasing biologics production to support market growth 113
TABLE 68 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 114
TABLE 69 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 114
TABLE 70 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 115
10.3.7 REST OF EUROPE 115
TABLE 71 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 115
TABLE 72 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 116
TABLE 73 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 116
10.4 ASIA PACIFIC 117
FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 117
10.4.1 ASIA PACIFIC: RECESSION IMPACT 118
TABLE 74 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 75 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 118
TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 119
TABLE 77 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.4.2 CHINA 120
10.4.2.1 China to dominate APAC market throughout forecast period 120
TABLE 78 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 120
TABLE 79 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 120
TABLE 80 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.4.3 JAPAN 121
10.4.3.1 Rising population and healthcare expenditure to favor market growth 121
TABLE 81 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 121
TABLE 82 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 122
TABLE 83 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 122
10.4.4 INDIA 123
10.4.4.1 Rising R&D investment to boost adoption of clinical trial imaging 123
TABLE 84 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 123
TABLE 85 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 124
TABLE 86 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 124
10.4.5 REST OF ASIA PACIFIC 125
TABLE 87 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 125
TABLE 88 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 125
TABLE 89 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 126
10.5 LATIN AMERICA 126
10.5.1 LOW COST OF RESOURCES, TAX ADVANTAGES TO ATTRACT PLAYER INTEREST 126
10.5.2 LATIN AMERICA: RECESSION IMPACT 127
TABLE 90 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 127
TABLE 91 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 127
TABLE 92 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 128
10.6 MIDDLE EAST & AFRICA 128
10.6.1 RISING RESEARCH FUNDING AND PARTNERSHIPS TO DRIVE MARKET 128
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 129
TABLE 93 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 129
TABLE 94 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 129
TABLE 95 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
11 COMPETITIVE LANDSCAPE 131
11.1 OVERVIEW 131
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 131
11.2.1 RIGHT-TO-WIN APPROACHES ADOPTED BY PLAYERS 131
TABLE 96 CLINICAL TRIAL IMAGING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 131
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 133
FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022) 133
11.4 MARKET SHARE ANALYSIS 133
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 133
TABLE 97 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION 134
11.5 COMPANY EVALUATION MATRIX (2022) 135
11.5.1 STARS 135
11.5.2 EMERGING LEADERS 135
11.5.3 PERVASIVE PLAYERS 135
11.5.4 PARTICIPANTS 135
FIGURE 31 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX, 2022 136
11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 137
11.6.1 PROGRESSIVE COMPANIES 137
11.6.2 STARTING BLOCKS 137
11.6.3 RESPONSIVE COMPANIES 137
11.6.4 DYNAMIC COMPANIES 137
FIGURE 32 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATIRX FOR STARTUPS/SMES, 2022 138
11.7 COMPETITIVE BENCHMARKING 138
FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF KEY PLAYERS 138
TABLE 98 COMPANY PRODUCT FOOTPRINT 139
TABLE 99 COMPANY GEOGRAPHICAL FOOTPRINT 139
11.8 COMPETITIVE SCENARIO 139
11.8.1 PRODUCT LAUNCHES & APPROVALS 139
TABLE 100 KEY PRODUCT LAUNCHES & APPROVALS (2020–2023) 139
11.8.2 DEALS 140
TABLE 101 KEY DEALS (2020–2023) 140
12 COMPANY PROFILES 141
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1 KEY PLAYERS 141
12.1.1 ICON PLC. 141
TABLE 102 ICON PLC.: BUSINESS OVERVIEW 141
FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2022) 142
12.1.2 BIOTELEMETRY (PHILIPS) 144
TABLE 103 BIOTELEMETRY: BUSINESS OVERVIEW 144
FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2022) 145
12.1.3 MEDPACE HOLDINGS INC. 147
TABLE 104 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 147
FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2022) 147
12.1.4 BIOMEDICAL SYSTEMS CORPORATION (ERT CLINICAL) 149
TABLE 105 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 149
12.1.5 BIOCLINICA INC. (CLARIO) 150
TABLE 106 BIOCLINICA INC.: BUSINESS OVERVIEW 150
12.1.6 IXICO PLC. 154
TABLE 107 IXICO PLC.: BUSINESS OVERVIEW 154
FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2022) 154
12.1.7 RESONANCE HEALTH ANALYSIS SERVICES (RESONANCE HEALTH) 157
TABLE 108 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW 157
FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2022) 157
12.1.8 RADIANT SAGE LLC 159
TABLE 109 RADIANT SAGE LLC: BUSINESS OVERVIEW 159
12.1.9 INTRINSIC IMAGING (WCG CLINICAL) 160
TABLE 110 WCG CLINICAL: BUSINESS OVERVIEW 160
12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES 161
TABLE 111 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW 161
12.2 OTHER PLAYERS 162
12.2.1 MEDICAL METRICS 162
12.2.2 PRISM CLINICAL IMAGING 163
12.2.3 BOSTON IMAGING CORE LAB 164
12.2.4 ANAGRAM 4 CLINICAL TRIALS 164
12.2.5 LYSCAUT MEDICAL IMAGING COMPANY 165
12.2.6 CALYX GROUP 165
12.2.7 BIOSPECTIVE 166
12.2.8 PROSCAN IMAGING 167
12.2.9 MICRON, INC. 167
12.2.10 IMAGING ENDPOINTS LI LLC. 168
12.2.11 PERSPECTUM 169
12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG GMBH 169
12.2.13 WORLDCARE CLINICAL 170
12.2.14 MEDIAN TECHNOLOGIES 170
12.2.15 INVICRO. LLC. 171
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX 172
13.1 DISCUSSION GUIDE 172
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 176
13.3 CUSTOMIZATION OPTIONS 178
13.4 RELATED REPORTS 178
13.5 AUTHOR DETAILS 179

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（clinical trial）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/20　10:26

143.76 円

160.81 円

193.57 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.